Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's me
CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ac
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
10:01am, Tuesday, 09'th Apr 2024
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom en
Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
07:30am, Wednesday, 28'th Feb 2024
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met , Statistical Significance (P
Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript
02:49pm, Thursday, 15'th Feb 2024
Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript
The 3 Best Penny Stocks to Buy in February 2024
07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
07:30am, Thursday, 15'th Feb 2024
Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Ora
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
07:30am, Friday, 09'th Feb 2024
CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
07:30am, Monday, 05'th Feb 2024
Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines ba
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
07:09pm, Thursday, 01'st Feb 2024
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns
Palatin Announces Closing of $10 Million Registered Direct Offering
04:00pm, Thursday, 01'st Feb 2024
CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mol
Palatin Announces $10 Million Registered Direct Offering
08:00am, Tuesday, 30'th Jan 2024
CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
01:38pm, Thursday, 11'th Jan 2024
After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosens, we c
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
10:33am, Monday, 08'th Jan 2024
Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Stud
